FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2998424882> ?p ?o ?g. }

• W2998424882 endingPage "1350" @default.
• W2998424882 startingPage "1341" @default.
• W2998424882 abstract "Purpose: Metaplastic breast cancer (BC) is an uncommon yet aggressive histologic subtype of BC. We sought to identify factors associated with its diagnosis and compare the management and outcomes of metaplastic BC with those of other BCs and triple negative invasive ductal carcinoma in particular given how often it has a triple negative phenotype. Patients and Methods: We identified women diagnosed with invasive BC in 2010-2014 in the National Cancer Data Base, and used univariate analysis to compare baseline patient and tumor characteristics by BC subtype. Overall survival (OS) was estimated with the Kaplan-Meier method, and multivariate Cox proportional hazards models were used to identify independent predictors of OS. Results: Of 247,355 cases, 2,084 (0.8%) were metaplastic BC, 55,998 (23%) triple negative BC, and 77% other BC. Relative to non-metaplastic BC, women with metaplastic BC were more likely to be older at diagnosis (median age, 62 vs. 59 years), have ≥1 comorbid conditions (22% vs. 18%), and be on Medicare (41% vs. 33%; P<0.001). Metaplastic BCs tended to be basal-like (77%), and relative to triple-negative or other BC, metaplastic BC was associated with higher clinical T status (cT3-4, 18% vs. 11%, 8%), no clinical nodal involvement (cN0, 86%, 77%, 80%), no lymphovascular invasion (72%, 65%, 62%), and high-grade tumors (71%, 77%, 35%) (P<0.001). Most metaplastic BCs were treated with mastectomy (58%), sentinel lymph node dissection (65%), chest wall or breast irradiation (74%), and chemotherapy (75%) as adjuvant therapy (60%). At a median follow-up time of 44.5 months, OS rates were lower for metaplastic BC than for triple-negative or other BC across all clinical stages at 5 years (stage I, 85%, 87%, 91%; II, 73%, 77%, 87%; III, 43%, 53%, 75%) and at 3 years (Stage IV, 15%, 22%, 64%; P<0.001). On multivariate analysis, increasing age, advanced clinical stage, lymphovascular invasion, axillary (vs. sentinel) node dissection, and no radiation or chemotherapy were associated with worse outcomes in metaplastic BC. Extent of surgery affected survival for triple-negative and other BC but not for metaplastic BC. Conclusion: Outcomes for metaplastic BC continue to be worse than those for other BC subtypes despite modern treatments. Optimizing systemic therapy options, which was a significant predictor of survival, should be a priority in managing metaplastic BC." @default.
• W2998424882 created "2020-01-10" @default.
• W2998424882 creator A5008692926 @default.
• W2998424882 creator A5014176442 @default.
• W2998424882 creator A5029066148 @default.
• W2998424882 creator A5084511205 @default.
• W2998424882 creator A5085458148 @default.
• W2998424882 creator A5089277393 @default.
• W2998424882 date "2020-01-01" @default.
• W2998424882 modified "2023-10-15" @default.
• W2998424882 title "Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes" @default.
• W2998424882 cites W1955397179 @default.
• W2998424882 cites W1966727713 @default.
• W2998424882 cites W1989663680 @default.
• W2998424882 cites W1997730866 @default.
• W2998424882 cites W2003790128 @default.
• W2998424882 cites W2004079062 @default.
• W2998424882 cites W2024992326 @default.
• W2998424882 cites W2048283099 @default.
• W2998424882 cites W2052882948 @default.
• W2998424882 cites W2054961739 @default.
• W2998424882 cites W2056875134 @default.
• W2998424882 cites W2070990075 @default.
• W2998424882 cites W2075894019 @default.
• W2998424882 cites W2077724220 @default.
• W2998424882 cites W2081395163 @default.
• W2998424882 cites W2106292881 @default.
• W2998424882 cites W2118605519 @default.
• W2998424882 cites W2135936056 @default.
• W2998424882 cites W2139398669 @default.
• W2998424882 cites W2139984188 @default.
• W2998424882 cites W2141589190 @default.
• W2998424882 cites W2160928966 @default.
• W2998424882 cites W2334317780 @default.
• W2998424882 cites W2551065090 @default.
• W2998424882 cites W2609874944 @default.
• W2998424882 cites W2733726834 @default.
• W2998424882 cites W2779175689 @default.
• W2998424882 cites W2781525129 @default.
• W2998424882 cites W2796106322 @default.
• W2998424882 cites W2805696891 @default.
• W2998424882 cites W2888075641 @default.
• W2998424882 cites W2934657692 @default.
• W2998424882 cites W2945644767 @default.
• W2998424882 doi "https://doi.org/10.7150/jca.40817" @default.
• W2998424882 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6995376" @default.
• W2998424882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32047541" @default.
• W2998424882 hasPublicationYear "2020" @default.
• W2998424882 type Work @default.
• W2998424882 sameAs 2998424882 @default.
• W2998424882 citedByCount "31" @default.
• W2998424882 countsByYear W29984248822020 @default.
• W2998424882 countsByYear W29984248822021 @default.
• W2998424882 countsByYear W29984248822022 @default.
• W2998424882 countsByYear W29984248822023 @default.
• W2998424882 crossrefType "journal-article" @default.
• W2998424882 hasAuthorship W2998424882A5008692926 @default.
• W2998424882 hasAuthorship W2998424882A5014176442 @default.
• W2998424882 hasAuthorship W2998424882A5029066148 @default.
• W2998424882 hasAuthorship W2998424882A5084511205 @default.
• W2998424882 hasAuthorship W2998424882A5085458148 @default.
• W2998424882 hasAuthorship W2998424882A5089277393 @default.
• W2998424882 hasBestOaLocation W29984248821 @default.
• W2998424882 hasConcept C121608353 @default.
• W2998424882 hasConcept C126322002 @default.
• W2998424882 hasConcept C143998085 @default.
• W2998424882 hasConcept C144301174 @default.
• W2998424882 hasConcept C2776047466 @default.
• W2998424882 hasConcept C2777757722 @default.
• W2998424882 hasConcept C2778740770 @default.
• W2998424882 hasConcept C2779013556 @default.
• W2998424882 hasConcept C2780110267 @default.
• W2998424882 hasConcept C2780862961 @default.
• W2998424882 hasConcept C38180746 @default.
• W2998424882 hasConcept C50382708 @default.
• W2998424882 hasConcept C530470458 @default.
• W2998424882 hasConcept C71924100 @default.
• W2998424882 hasConcept C90924648 @default.
• W2998424882 hasConceptScore W2998424882C121608353 @default.
• W2998424882 hasConceptScore W2998424882C126322002 @default.
• W2998424882 hasConceptScore W2998424882C143998085 @default.
• W2998424882 hasConceptScore W2998424882C144301174 @default.
• W2998424882 hasConceptScore W2998424882C2776047466 @default.
• W2998424882 hasConceptScore W2998424882C2777757722 @default.
• W2998424882 hasConceptScore W2998424882C2778740770 @default.
• W2998424882 hasConceptScore W2998424882C2779013556 @default.
• W2998424882 hasConceptScore W2998424882C2780110267 @default.
• W2998424882 hasConceptScore W2998424882C2780862961 @default.
• W2998424882 hasConceptScore W2998424882C38180746 @default.
• W2998424882 hasConceptScore W2998424882C50382708 @default.
• W2998424882 hasConceptScore W2998424882C530470458 @default.
• W2998424882 hasConceptScore W2998424882C71924100 @default.
• W2998424882 hasConceptScore W2998424882C90924648 @default.
• W2998424882 hasIssue "6" @default.
• W2998424882 hasLocation W29984248821 @default.
• W2998424882 hasLocation W29984248822 @default.
• W2998424882 hasLocation W29984248823 @default.
• W2998424882 hasLocation W29984248824 @default.

• next